AL-LAD vs 1cP-AL-LAD

AL-LAD (6-allyl-6-nor-LSD) is a lysergamide psychedelic closely related to LSD, differing by replacement of the N6 methyl group with an allyl group. Like other serotonergic hallucinogens it acts primarily through agonism at the 5-HT2A receptor, and in the mouse head-twitch response assay it produces the characteristic inverted U-shaped dose-response curve, proving only slightly less potent than LSD itself. Users describe strongly visual, colorful effects with a duration comparable to LSD but often somewhat shorter and milder in strength and comedown. Analytical and metabolic studies have detailed its structure, biotransformation, and its acylated prodrug forms such as 1P-AL-LAD and 1cP-AL-LAD, which are hydrolyzed to AL-LAD in the body. A published case of fatal ventricular dysrhythmia associated with its use indicates that, despite its reputation as a gentler LSD analogue, it is not without cardiovascular risk.

effects

Serotonin

targets

5-HT2A receptor, 5-HT2C receptor, 5-HT1A receptor

suppliers

reference only

1cP-AL-LAD is a doubly modified lysergamide carrying a cyclopropanecarbonyl group on the indole nitrogen of AL-LAD (6-allyl-6-nor-LSD), and it was first formally identified in seized blotter products in Japan. By analogy with other N1-acyl lysergamides it is presumed to act as a prodrug that is cleaved in the body to AL-LAD, a colorful 5-HT2A receptor agonist generally described as comparatively short and gentle. Its parent AL-LAD is equipotent to slightly less potent than LSD in the mouse head-twitch assay, whereas the metabolic pathways and biological activity of 1cP-AL-LAD itself have not yet been directly characterized. The available literature is largely forensic and analytical, reflecting its recent and limited emergence on the new psychoactive substance market.

effects

Serotonin

targets

5-HT2A receptor, 5-HT2C receptor, 5-HT1A receptor

suppliers

reference only